MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor

FEBS Journal

Volumn 279, Issue 20, 2012, Pages 3800-3812

  Liu, Lingxiang ^a   Shao, Xiaoyan ^b   Gao, Wen ^a   Zhang, Zhi ^c   Liu, Ping ^a   Wang, Rongsheng ^a   Huang, Puwen ^a   Yin, Yongmei ^a   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

epidermal growth factor receptor (EGFR); microRNA; miR 133b; non small cell lung cancer; targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MESSENGER RNA; MICRORNA; MICRORNA 133B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CHEMOSENSITIVITY; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EGFR GENE; FEMALE; GENE; GENE EXPRESSION; GENE INTERACTION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; NUCLEOTIDE SEQUENCE; PLEURA METASTASIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; VESSEL INVASION;

3' UNTRANSLATED REGIONS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84867102786     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08741.x     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, &, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
2. Murphy M, &, Stordal B, (2011) Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist Updat 14, 177-190.
3. Liang Z, Zhang J, Zeng X, Gao J, Wu S, &, Liu T, (2010) Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer 10, 376-384.
4. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, et al,. (2007) Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18, 752-760.
5. Mathonnet G, Fabian MR, Svitkin YV, Parsyan A, Huck L, Murata T, Biffo S, Merrick WC, Darzynkiewicz E, Pillai RS, et al,. (2007) MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science, 317, 1764-1767.
6. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J, Helfrich BA, et al,. (2008) EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 19, 1053-1059.
7. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, &, Massague J, (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152.
8. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al,. (2005) A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353, 1793-1801.
9. Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, Meijer GA, &, Agami R, (2008) Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 68, 5795-5802.
10. Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, et al,. (2008) Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 123, 1616-1622.
11. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, &, Croce CM, (2007) MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297, 1901-1908.
12. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, &, Visakorpi T, (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67, 6130-6135.
13. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, &, Slack FJ, (2007) MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 67, 11111-11116.
14. Wang Y, Wang X, Zhang J, Sun G, Luo H, Kang C, Pu P, Jiang T, Liu N, &, You Y, (2012) MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas. J Neurooncol 106, 217-224.
15. Kang JU, Koo SH, Kwon KC, Park JW, Shin SY, Kim JM, &, Jung SS, (2007) High frequency of genetic alterations in non-small cell lung cancer detected by multi-target fluorescence in situ hybridization. J Korean Med Sci 22 (Suppl), S47-S51.
16. Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, Otterson GA, &, Nana-Sinkam SP, (2009) MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun 388, 483-489.
17. de Mena L, Coto E, Cardo LF, Diaz M, Blazquez M, Ribacoba R, Salvador C, Pastor P, Samaranch L, Moris G, et al,. (2010) Analysis of the micro-RNA-133 and PITX3 genes in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 153B, 1234-1239.
18. Xiao L, Xiao J, Luo X, Lin H, Wang Z, &, Nattel S, (2008) Feedback remodeling of cardiac potassium current expression: a novel potential mechanism for control of repolarization reserve. Circulation 118, 983-992.
19. Koutsoulidou A, Mastroyiannopoulos NP, Furling D, Uney JB, &, Phylactou LA, (2011) Expression of miR-1, miR-133a, miR-133b and miR-206 increases during development of human skeletal muscle. BMC Dev Biol 11, 34-42.
20. Zeiger U, &, Khurana TS, (2010) Distinctive patterns of microRNA expression in extraocular muscles. Physiol Genomics 41, 289-296.
21. Kozakowska M, Ciesla M, Stefanska A, Skrzypek K, Was H, Jazwa A, Grochot-Przeczek A, Kotlinowski J, Szymula A, Bartelik A, et al,. (2012) Heme oxygenase-1 inhibits myoblast differentiation by targeting myomirs. Antioxid Redox Signal 16, 113-127.
22. Palmieri A, Pezzetti F, Brunelli G, Zollino I, Scapoli L, Martinelli M, Arlotti M, &, Carinci F, (2007) Differences in osteoblast miRNA induced by cell binding domain of collagen and silicate-based synthetic bone. J Biomed Sci 14, 777-782.
23. Haas JD, Nistala K, Petermann F, Saran N, Chennupati V, Schmitz S, Korn T, Wedderburn LR, Forster R, Krueger A, et al,. (2011) Expression of miRNAs miR-133b and miR-206 in the Il17a/f locus is co-regulated with IL-17 production in alphabeta and gammadelta T cells. PLoS One 6, e20171.
24. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, Kempf T, Wollert KC, &, Thum T, (2011) Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 51, 872-875.
25. Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam SP, &, Lee LJ, (2011) MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm 8, 1381-1389.
26. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, &, Matsubara H, (2010) miR-145, miR-133a and miR-133b: tumor suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127, 2804-2814.
27. Akcakaya P, Ekelund S, Kolosenko I, Caramuta S, Ozata DM, Xie H, Lindforss U, Olivecrona H, &, Lui WO, (2011) miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol 39, 311-318.
28. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, &, Wang Y, (2009) Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 24, 652-657.
29. Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W, &, Li H, (2010) Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev 11, 905-911.
30. Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, Wai-Man Ng R, &, Ignace Wei W, (2008) Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 123, 251-257.
31. Qin W, Dong P, Ma C, Mitchelson K, Deng T, Zhang L, Sun Y, Feng X, Ding Y, Lu X, et al,. (2011) MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. Oncogene in press, doi: 10.1038/onc.2011.561.
32. Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, &, Yakhini Z, (2009) Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 4, e8003.
33. Hu G, Chen D, Li X, Yang K, Wang H, &, Wu W, (2010) miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol Ther 10, 190-197.
34. Du L, &, Pertsemlidis A, (2011) Cancer and neurodegenerative disorders: pathogenic convergence through microRNA regulation. J Mol Cell Biol 3, 176-180.
35. Brodersen P, &, Voinnet O, (2009) Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol 10, 141-148.
36. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, &, Burgess AW, (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284, 31-53.
37. Ogata T, Teshima T, Inaoka M, Minami K, Tsuchiya T, Isono M, Furusawa Y, &, Matsuura N, (2011) Carbon ion irradiation suppresses metastatic potential of human non-small cell lung cancer A549 cells through the phosphatidylinositol-3-kinase/Akt signaling pathway. J Radiat Res 52, 374-379.
38. Mercer KE, &, Pritchard CA, (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653, 25-40.
39. Langlois B, Perrot G, Schneider C, Henriet P, Emonard H, Martiny L, &, Dedieu S, (2010) LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways. PLoS One 5, e11584.
40. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, et al,. (2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96, 1133-1141.
41. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al,. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
42. Weinstein IB, (2002) Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297, 63-64.
43. Pietanza MC, Lynch TJ Jr, Lara PN Jr, Cho J, Yanagihara RH, Vrindavanam N, Chowhan NM, Gadgeel SM, Pennell NA, Funke R, et al,. (2012) XL647-A multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol 7, 219-226.
44. Spigel D, Ervin T, Ramlau R, Daniel D, Goldschmidt J, Blumenschein G, Krzakowski M, Robinet G, Clement-Duchene C, &, Barlesi F, (2011) Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29, Abstract No. 7505.
45. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, &, Sobin L, (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2, 706-714.
46. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, &, Sobin LH, (1999) Histological Typing of Lung and Pleural Tumours, 3rd edn. Berlin, Springer-Verlag.
47. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, &, Haley JD, (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65, 9455-9462.
48. Sordella R, Bell DW, Haber DA, &, Settleman J, (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167.
49. Livak KJ, &, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408.
50. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, 2002-2007.